Skip to main content

Advertisement

Table 1 Correlation between TCTN1 expression and clinicopathologic characteristics of 110 GBM patients in the Chinese cohort

From: Expression and prognostic significance of TCTN1 in human glioblastoma

Characteristics No. patients TCTN1 expression P*
Low High
Gender     0.378
 Male 74(67.3%) 20(27.0%) 54(73.0%)  
 Female 36(32.7%) 13(36.1%) 23(63.9%)  
Age (year)     0.211
 ≥53 52(47.3%) 19(36.5%) 33(63.5%)  
 <53 58(52.7%) 14(24.1%) 44(75.9%)  
Tumor origin     0.670
 Primary 95(86.4%) 28(29.5%) 67(70.5%)  
 Secondary 15(13.6%) 5(33.3%) 10(66.7%)  
Seizure     0.349
 No 96(87.3%) 27(28.1%) 69(71.9%)  
 Yes 14(12.7%) 6(42.9%) 8(57.1%)  
IICP     0.836
 No 59(53.6%) 17(28.8%) 42(71.2%)  
 Yes 51(46.4%) 16(31.4%) 35(68.6%)  
Cystic degeneration     0.799
 No 82(74.5%) 25(30.5%) 57(69.5%)  
 Yes 23(20.9%) 6(26.1%) 17(73.9%)  
Necrosis     0.419
 No 90(81.8%) 25(27.8%) 65(72.2%)  
 Yes 20(18.2%) 8(40.0%) 12(60.0%)  
Edge     0.762
 Not clear 52(47.3%) 15(28.8%) 37(71.2%)  
 Clear 17(15.5%) 6(35.3%) 11(64.7%)  
MTD (cm)     0.093
 < 5 46(41.8%) 18(39.1%) 28(60.9%)  
 ≥5 64(58.2%) 15(23.4%) 49(76.6%)  
Resection     1.000
 ≥98% 84(76.4%) 25(29.8%) 59(70.2%)  
 < 98% 26(23.6%) 8(30.8%) 18(69.2%)  
  1. *P value was evaluated by Fisher's Exact Test (2-sided).
  2. Abbreviations: IICP, increased intracranial pressure; MTD, mean tumor diameter.